文献速递临床试验与 GCP流行病学与生物统计

阿莫地喹及结构相关抗疟药的心血管效应:个体患者数据荟萃分析

The cardiovascular effects of amodiaquine and structurally related antimalarials: An individual patient data meta-analysis.
PubMed 文献 · PLoS Med · 2021-09-07

该个体患者数据荟萃分析纳入4项随机对照试验的2681例无并发症疟疾患者,评估阿莫地喹及结构相关抗疟药对QT间期和心率的影响。阿莫地喹延长QTcS(平均16.9 ms)少于氯喹和哌喹但多于本芴醇和咯萘啶;在≥12岁人群中阿莫地喹降低心率更明显并增加症状性窦性心动过缓风险。结论认为在WHO推荐剂量下单独或联合使用阿莫地喹及结构相关抗疟药是安全的。

要点

  • 阿莫地喹延长QTcS平均16.9 ms,小于氯喹和哌喹,大于本芴醇和咯萘啶。
  • ≥12岁人群阿莫地喹降低心率平均15.2 bpm,增加窦性心动过缓风险。
  • ≥12岁患者合用减慢心率药物或有心律失常风险时需谨慎使用阿莫地喹。

核心结论

  • 在WHO推荐剂量下,阿莫地喹及结构相关抗疟药单独或联合用于疟疾治疗和预防是安全的。

研究设计与样本

  • 个体患者数据荟萃分析,纳入4项随机对照试验的2681例无并发症疟疾患者。

主要发现

  • 阿莫地喹延长QTcS平均16.9 ms(95% CI: 15.0 to 18.8),小于氯喹21.9 ms(18.3 to 25.6,p=0.0069)和哌喹19.2 ms(15.8 to 20.5,p=0.0495),大于本芴醇5.6 ms(2.9 to 8.2,p<0.001)和咯萘啶-1.2 ms(-3.6 to +1.3,p<0.001)。
  • 在≥12岁人群中,阿莫地喹降低心率平均15.2 bpm(95% CI: 13.4 to 17.0),大于哌喹10.5 bpm(7.7 to 13.3,p=0.0013)、本芴醇9.3 bpm(6.4 to 12.2,p<0.001)、咯萘啶6.6 bpm(4.0 to 9.3,p<0.001)和氯喹5.9 bpm(3.2 to 8.5,p<0.001)。
  • 阿莫地喹相比本芴醇增加症状性窦性心动过缓(≤50 bpm)风险差异14.8%(95% CI: 5.4 to 24.3,p=0.0021),相比氯喹风险差异8.0%(95% CI: 4.0 to 12.0,p<0.001)。
  • 阿莫地喹对<12岁儿童心率的影响与其他抗疟药相比无临床意义。

关键数值与推荐

  • ≥12岁患者合用减慢心率药物、有严重心脏传导障碍或尖端扭转型室速风险因素时,应谨慎使用阿莫地喹。

临床怎么用

  • ≥12岁患者使用阿莫地喹前应评估心率相关风险及合并用药。
  • 阿莫地喹在WHO推荐剂量下用于疟疾治疗和预防总体安全。

局限性

  • 多数纳入患者缺乏个体患者水平的不良事件数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Amodiaquine is a 4-aminoquinoline antimalarial similar to chloroquine that is used extensively for the treatment and prevention of malaria. Data on the cardiovascular effects of amodiaquine are scarce, although transient effects on cardiac electrophysiology (electrocardiographic QT interval prolongation and sinus bradycardia) have been observed. We conducted an individual patient data meta-analysis to characterise the cardiovascular effects of amodiaquine and thereby support development of risk minimisation measures to improve the safety of this important antimalarial. METHODS AND FINDINGS: Studies of amodiaquine for the treatment or prevention of malaria were identified from a systematic review. Heart rates and QT intervals with study-specific heart rate correction (QTcS) were compared within studies and individual patient data pooled for multivariable linear mixed effects regression. The meta-analysis included 2,681 patients from 4 randomised controlled trials evaluating artemisinin-based combination therapies (ACTs) containing amodiaquine (n = 725), lumefantrine (n = 499), piperaquine (n = 716), and pyronaridine (n = 566), as well as monotherapy with chloroquine (n = 175) for uncomplicated malaria. Amodiaquine prolonged QTcS (mean = 16.9 ms, 95% CI: 15.0 to 18.8) less than chloroquine (21.9 ms, 18.3 to 25.6, p = 0.0069) and piperaquine (19.2 ms, 15.8 to 20.5, p = 0.0495), but more than lumefantrine (5.6 ms, 2.9 to 8.2, p < 0.001) and pyronaridine (-1.2 ms, -3.6 to +1.3, p < 0.001). In individuals aged ≥12 years, amodiaquine reduced heart rate (mean reduction = 15.2 beats per minute [bpm], 95% CI: 13.4 to 17.0) more than piperaquine (10.5 bpm, 7.7 to 13.3, p = 0.0013), lumefantrine (9.3 bpm, 6.4 to 12.2, p < 0.001), pyronaridine (6.6 bpm, 4.0 to 9.3, p < 0.001), and chloroquine (5.9 bpm, 3.2 to 8.5, p < 0.001) and was associated with a higher risk of potentially symptomatic sinus bradycardia (≤50 bpm) than lumefantrine (risk difference: 14.8%, 95% CI: 5.4 to 24.3, p = 0.0021) and chloroquine (risk difference: 8.0%, 95% CI: 4.0 to 12.0, p < 0.001). The effect of amodiaquine on the heart rate of children aged <12 years compared with other antimalarials was not clinically significant. Study limitations include the unavailability of individual patient-level adverse event data for most included participants, but no serious complications were documented. CONCLUSIONS: While caution is advised in the use of amodiaquine in patients aged ≥12 years with concomitant use of heart rate-reducing medications, serious cardiac conduction disorders, or risk factors for torsade de pointes, there have been no serious cardiovascular events reported after amodiaquine in widespread use over 7 decades. Amodiaquine and structurally related antimalarials in the World Health Organization (WHO)-recommended dose regimens alone or in ACTs are safe for the treatment and prevention of malaria.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Chan XHS, Haeusler IL, Win YN, et al. The cardiovascular effects of amodiaquine and structurally related antimalarials: An individual patient data meta-analysis. PLoS Med. 2021. PMID: 34492005. doi:10.1371/journal.pmed.1003766

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。